<DOC>
	<DOCNO>NCT01490450</DOCNO>
	<brief_summary>The purpose study characterize safety , efficacy dose response BMS-945429 subject active Psoriatic Arthritis inadequate response Nonsteroidal anti-inflammatory drug ( NSAIDs ) non-biologic Disease modify anti-rheumatic drug ( DMARDs ) .</brief_summary>
	<brief_title>Psoriatic Arthritis Dose Ranging Study BMS-945429 Subjects Who Are Not Responding NSAIDs Non-biologic Disease Modifying Anti-rheumatic Drugs ( DMARDs ) Therapy</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Psoriatic</mesh_term>
	<mesh_term>Antirheumatic Agents</mesh_term>
	<criteria>Must stable background Methotrexate ( MTX ) therapy prior Day1/Randomization . Subjects must take MTX least 3 month dose ≥ 15 mg/week maximum weekly dose ≤ 25 mg/week , stable dose 4 week prior randomization ( Day 1 ) . Methotrexate dose ≥ 15 mg/week efficacious decrease due toxicity low 10 mg/week allow Inadequate response NSAID and/or nonbiologic DMARD Minimum 3 swell 3 tender joint Active psoriatic skin lesion minimum 3 % body surface area high sensitivity Creactive protein ( hsCRP ) ≥ 0.3 mg/dL Previously receive currently receive concomitant biologic therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>